View in EDS

Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.

Saved in:
Bibliographic Details
Title: Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.
Authors: Al-Jarshawi M; Centre for Health Informatics, Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. mustafa.al-jarshawi@manchester.ac.uk.; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK. mustafa.al-jarshawi@manchester.ac.uk.; Honorary Clinical Lecturer, Institute of Health Sciences Education, Queen Mary University of London, London, UK. mustafa.al-jarshawi@manchester.ac.uk.; Council Member, European Society of Cardiology (ESC) Council of Cardio-Oncology, Sophia Antipolis, France. mustafa.al-jarshawi@manchester.ac.uk.; NIHR Academy member, National Institute for Health & Care Research, Leeds, UK. mustafa.al-jarshawi@manchester.ac.uk., Cole A; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK., Bagur R; Department of Cardiology, London Health Sciences Centre, Western University, London, ON, Canada., Wang HY; Coronary Heart Disease Center and Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Ng CH; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore., Yu D; School of Medicine, Keele University, Keele, UK., Chew NWS; Department of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore., Mamas MA; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK.
Source: Cardiovascular diabetology. Endocrinology reports [Cardiovasc Diabetol Endocrinol Rep] 2026 May 22; Vol. 12 (1). Date of Electronic Publication: 2026 May 22.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 9918994893106676 Publication Model: Electronic Cited Medium: Internet ISSN: 3059-4057 (Electronic) Linking ISSN: 30594057 NLM ISO Abbreviation: Cardiovasc Diabetol Endocrinol Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42169198
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Al-Jarshawi+M%22">Al-Jarshawi M</searchLink>; Centre for Health Informatics, Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. mustafa.al-jarshawi@manchester.ac.uk.; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK. mustafa.al-jarshawi@manchester.ac.uk.; Honorary Clinical Lecturer, Institute of Health Sciences Education, Queen Mary University of London, London, UK. mustafa.al-jarshawi@manchester.ac.uk.; Council Member, European Society of Cardiology (ESC) Council of Cardio-Oncology, Sophia Antipolis, France. mustafa.al-jarshawi@manchester.ac.uk.; NIHR Academy member, National Institute for Health & Care Research, Leeds, UK. mustafa.al-jarshawi@manchester.ac.uk.<br /><searchLink fieldCode="AU" term="%22Cole+A%22">Cole A</searchLink>; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK.<br /><searchLink fieldCode="AU" term="%22Bagur+R%22">Bagur R</searchLink>; Department of Cardiology, London Health Sciences Centre, Western University, London, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Wang+HY%22">Wang HY</searchLink>; Coronary Heart Disease Center and Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Ng+CH%22">Ng CH</searchLink>; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Yu+D%22">Yu D</searchLink>; School of Medicine, Keele University, Keele, UK.<br /><searchLink fieldCode="AU" term="%22Chew+NWS%22">Chew NWS</searchLink>; Department of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Mamas+MA%22">Mamas MA</searchLink>; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918994893106676%22">Cardiovascular diabetology. Endocrinology reports</searchLink> [Cardiovasc Diabetol Endocrinol Rep] 2026 May 22; Vol. 12 (1). <i>Date of Electronic Publication: </i>2026 May 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9918994893106676 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>3059-4057 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2230594057%22">30594057 </searchLink><i>NLM ISO Abbreviation: </i>Cardiovasc Diabetol Endocrinol Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42169198
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s40842-026-00299-z
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Al-Jarshawi M
      – PersonEntity:
          Name:
            NameFull: Cole A
      – PersonEntity:
          Name:
            NameFull: Bagur R
      – PersonEntity:
          Name:
            NameFull: Wang HY
      – PersonEntity:
          Name:
            NameFull: Ng CH
      – PersonEntity:
          Name:
            NameFull: Yu D
      – PersonEntity:
          Name:
            NameFull: Chew NWS
      – PersonEntity:
          Name:
            NameFull: Mamas MA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 05
              Text: 2026 May 22
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 3059-4057
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cardiovascular diabetology. Endocrinology reports
              Type: main
ResultId 1